Study guide
4.1 Diabetes Mellitus & Endocrine Emergencies
Clinical Officers Council Pre-Internship Examination Kenya
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Overview & Exam Strategy
1.1 About the COC Pre-Internship Examination 1.2 Clinical Decision-Making & Preparation Strategy
2 Chapter 2: Infectious & Communicable Diseases (Internal Medicine)
2.1 Malaria Diagnosis & Case Management 2.2 Tuberculosis & Leprosy Control 2.3 HIV/AIDS & Opportunistic Infections 2.4 Enteric & Neglected Tropical Infections
3 Chapter 3: Cardiovascular & Respiratory Medicine (Internal Medicine)
3.1 Hypertension & Cardiovascular Disorders 3.2 Respiratory Disorders & Acute Emergencies 3.3 Venous Thromboembolism & Vascular Emergencies
4 Chapter 4: Metabolic, Gastrointestinal & Neurological Medicine (Internal Medicine)
4.1 Diabetes Mellitus & Endocrine Emergencies 4.2 Gastrointestinal & Hepatorenal Disorders 4.3 Neurological Emergencies & Acute Toxicology
5 Chapter 5: Trauma Resuscitation & Emergency Surgery (General Surgery)
5.1 ATLS Primary Survey & Trauma Resuscitation 5.2 Burn Assessment & Fluid Resuscitation 5.3 Surgical Wounds, Infections & Tetanus Prophylaxis
6 Chapter 6: Acute Abdomen & Gastrointestinal Surgery (General Surgery)
6.1 Acute Appendicitis & Peritonitis 6.2 Intestinal Obstruction & Abdominal Hernias 6.3 Hepatobiliary, Pancreatic & Anorectal Surgical Conditions
7 Chapter 7: Orthopedics, Urology & Special Surgical Emergencies (General Surgery)
7.1 Fractures, Dislocations & Cast Management 7.2 Acute Compartment Syndrome & Limb Emergencies 7.3 Urological Emergencies & Pelvic Trauma 7.4 Emergency Airway, Anesthesia & Oncology Screening
8 Chapter 8: Essential Newborn Care & Neonatal Conditions (Pediatrics)
8.1 Immediate Newborn Care & Neonatal Resuscitation 8.2 Neonatal Jaundice, Sepsis & Common Disorders 8.3 Low Birth Weight & Kangaroo Mother Care
9 Chapter 9: IMCI Guidelines & Common Pediatric Conditions (Pediatrics)
9.1 IMCI Principles & General Danger Signs 9.2 Cough, Fast Breathing & Pediatric Pneumonia 9.3 Pediatric Diarrheal Diseases & Dehydration 9.4 Acute Pediatric Infections: Meningitis, Croup & Febrile Seizures
10 Chapter 10: Child Nutrition, KEPI & Preventive Pediatrics (Pediatrics)
10.1 Severe Acute Malnutrition (SAM) Management 10.2 KEPI Immunization Schedule & Vaccine Logistics 10.3 Pediatric Prophylaxis & Early Infant Diagnosis
11 Chapter 11: Antenatal Care & Medical Complications of Pregnancy (Obstetrics & Gynecology)
11.1 Focused Antenatal Care & Routine ANC Screening 11.2 Hypertensive Disorders of Pregnancy & Eclampsia 11.3 Medical Disorders & Infections in Pregnancy
12 Chapter 12: Labor, Delivery & Obstetric Emergencies (Obstetrics & Gynecology)
12.1 Normal Labor & Partograph Monitoring 12.2 Active Management of the Third Stage of Labor & PPH 12.3 Antepartum Hemorrhage & Uterine Rupture 12.4 Induction of Labor & Malpresentation Emergencies
13 Chapter 13: Puerperium, Gynecological Disorders & Family Planning (Obstetrics & Gynecology)
13.1 Puerperal Sepsis & Postnatal Complications 13.2 Pelvic Inflammatory Disease & Gynecological Conditions 13.3 Modern Contraceptive Technology & WHO MEC Criteria
14 Chapter 14: Primary Health Care & Devolved Health Systems (Community Health)
14.1 Primary Health Care Principles & Universal Health Coverage 14.2 Kenya Health Service Delivery Structure & Devolved Governance 14.3 Kenya Community Health Strategy & Level 1 Services
15 Chapter 15: Epidemiology, Disease Surveillance & Outbreak Response (Community Health)
15.1 Epidemiological Principles & Health Indicators 15.2 Integrated Disease Surveillance and Response (IDSR) 15.3 Vector Control & Neglected Tropical Diseases
16 Chapter 16: Environmental Health, Waste Management & Cold Chain (Community Health)
16.1 Water Quality & Household Water Treatment 16.2 Community Sanitation & Excreta Disposal 16.3 Healthcare Waste Management & Infection Prevention Control 16.4 Vaccine Cold Chain Management & Quality Monitoring
17 Chapter 17: Health Systems Management — Leadership, Policy & Financing
17.1 Management Functions, Leadership & Supportive Supervision 17.2 Kenya Health Policy, Planning & the Devolved Budget Cycle 17.3 Health Financing & Universal Health Coverage under the Social Health Authority 17.4 Human Resource Management, Scheme of Service & Performance Appraisal
18 Chapter 18: Health Commodities, Information & Quality Management
18.1 Health Commodity & Supply Chain Management (KEMSA) 18.2 Health Information Systems, Records & KHIS Reporting 18.3 Quality Improvement, Clinical Audit & Patient Safety
19 Chapter 19: Professional Practice, Ethics & Medico-Legal Responsibility
19.1 Scope of Practice, Registration, Licensing & Professional Discipline 19.2 Medical Ethics, Informed Consent & Patient Rights 19.3 Medico-Legal Documentation, Statutory Notification & Facility Safety Governance
4.1 Diabetes Mellitus & Endocrine Emergencies
Key Takeaways Explain This Topic AI
The Kenya National Guidelines for the Prevention and Management of Non-Communicable Diseases define Diabetes Mellitus by Fasting Plasma Glucose >= 7.0 mmol/L, 2-hour post-load glucose >= 11.1 mmol/L during a 75g OGTT, HbA1c >= 6.5%, or a random plasma glucose >= 11.1 mmol/L accompanied by classic osmotic symptoms (polyuria, polydipsia, unexplained weight loss).
Metformin (titrated from 500 mg to a maximum of 2000 mg daily with meals) is the foundational first-line oral agent for Type 2 Diabetes; dose reduction is mandatory at eGFR 30–44 mL/min, and it is strictly contraindicated at eGFR < 30 mL/min due to the risk of lactic acidosis.
Diabetic Ketoacidosis (DKA) is defined by the diagnostic triad of hyperglycemia (> 14.0 mmol/L), ketonemia/ketonuria (>= ++), and high anion gap metabolic acidosis (arterial pH < 7.30 or serum bicarbonate < 15 mmol/L); initial management prioritizes aggressive isotonic fluid resuscitation, low-dose soluble insulin (0.1 units/kg/hr), and strict potassium monitoring.
In DKA resuscitation, insulin infusion must be withheld if serum potassium is < 3.3 mmol/L until hypokalemia is corrected; potassium (20–30 mEq KCl/L fluid) must be added when serum K+ is 3.5–5.0 mmol/L, and IV fluids must transition to 5% Dextrose with saline when blood glucose drops below 14.0 mmol/L to prevent cerebral edema.
Endocrine emergencies require rapid differentiation: Hyperosmolar Hyperglycemic State (profound glucose > 33.3 mmol/L, effective serum osmolality > 320 mOsm/kg, absent ketoacidosis), Thyroid Storm (hyperpyrexia, tachycardia, delirium; managed with propranolol, PTU, Lugol's iodine, and hydrocortisone), and Myxedema Coma (hypothermia, bradycardia, stupor; managed with IV levothyroxine, stress-dose hydrocortisone, and passive rewarming).
Last updated: September 2026
4.1 Diabetes Mellitus & Endocrine Emergencies
Core Clinical Rule: In the emergency management of Diabetic Ketoacidosis (DKA) , never administer an insulin bolus or start an insulin infusion if the serum potassium is < 3.3 mmol/L ; potassium must be aggressively replaced first to prevent fatal ventricular arrhythmias and respiratory arrest. Furthermore, when plasma glucose falls below 14.0 mmol/L , intravenous fluids must immediately be transitioned to 5% Dextrose in 0.9% Normal Saline to prevent rapid osmotic fluid shifts across the blood-brain barrier and catastrophic cerebral edema .
Endocrine and metabolic disorders represent a significant proportion of acute medical admissions and chronic outpatient visits across Kenyan healthcare facilities. According to the Kenya National STEPwise Survey for Non-Communicable Diseases (NCDs), the national adult prevalence of diabetes mellitus is approximately 3.3%, with over 60% of affected Kenyans remaining undiagnosed until presenting with advanced microvascular or life-threatening acute metabolic decompensation. For the Clinical Officer intern, mastery of diagnostic thresholds, oral and injectable regimens, renal precautions, and acute endocrine resuscitation algorithms is foundational for clinical practice and national licensure.
- 1. Kenya National Guidelines for the Diagnosis of Diabetes Mellitus
- Standard Diagnostic Criteria
According to the Kenya National Guidelines for the Prevention and Management of Non-Communicable Diseases (Ministry of Health), the diagnosis of Diabetes Mellitus is confirmed when any one of the following criteria is met on venous plasma:
Diagnostic Test Normal Range Impaired / Prediabetes Diabetes Mellitus Threshold
Fasting Plasma Glucose (FPG) < 5.6 mmol/L < 5.6\text{ mmol/L} < 5.6 mmol/L ( < 100 mg/dL < 100\text{ mg/dL} < 100 mg/dL ) 5.6 − 6.9 mmol/L 5.6 - 6.9\text{ mmol/L} 5.6 − 6.9 mmol/L (Impaired Fasting Glucose - IFG) ≥ 7.0 mmol/L \ge 7.0\text{ mmol/L} ≥ 7.0 mmol/L ( ≥ 126 mg/dL \ge 126\text{ mg/dL} ≥ 126 mg/dL )
2-Hour Post-Load Glucose (75g OGTT) < 7.8 mmol/L < 7.8\text{ mmol/L} < 7.8 mmol/L ( < 140 mg/dL < 140\text{ mg/dL} < 140 mg/dL ) 7.8 − 11.0 mmol/L 7.8 - 11.0\text{ mmol/L} 7.8 − 11.0 mmol/L (Impaired Glucose Tolerance - IGT) ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L ( ≥ 200 mg/dL \ge 200\text{ mg/dL} ≥ 200 mg/dL )
Glycated Hemoglobin (HbA1c) < 5.7 % < 5.7\% < 5.7% ( < 39 mmol/mol < 39\text{ mmol/mol} < 39 mmol/mol ) 5.7 % − 6.4 % 5.7\% - 6.4\% 5.7% − 6.4% ( 39 − 47 mmol/mol 39 - 47\text{ mmol/mol} 39 − 47 mmol/mol ) ≥ 6.5 % \ge 6.5\% ≥ 6.5% ( ≥ 48 mmol/mol \ge 48\text{ mmol/mol} ≥ 48 mmol/mol )
Random Plasma Glucose (RPG) N/A N/A ≥ 11.1 mmol/L \ge 11.1\text{ mmol/L} ≥ 11.1 mmol/L ( ≥ 200 mg/dL \ge 200\text{ mg/dL} ≥ 200 mg/dL ) with classic symptoms
Clinical Testing Pearls:
Fasting is defined as no caloric intake for at least 8 hours .
In the absence of unequivocal symptomatic hyperglycemia (classic osmotic triad of polyuria, polydipsia, and unexplained weight loss) or acute hyperglycemic crisis, a single abnormal laboratory test must be confirmed by repeat testing on a subsequent day using a fresh venous blood sample.
Capillary point-of-care glucometer strips are recommended for screening and monitoring; however, venous plasma laboratory confirmation is the standard for formal diagnosis.
HbA1c must be measured using a method certified by the National Glycohemoglobin Standardization Program (NGSP). In conditions with altered erythrocyte turnover (e.g., sickle cell anemia, severe malaria, pregnancy, recent blood transfusion, end-stage renal disease), HbA1c is unreliable, and plasma glucose criteria must be used exclusively.
- 2. Outpatient Pharmacotherapy of Type 2 Diabetes Mellitus [Newly Diagnosed Type 2 Diabetes Mellitus]
- |
- +-------------------+-------------------+
- | |
- [HbA1c < 8.5% and [HbA1c >= 8.5% or
- Symptomatically Stable] Symptomatic / Catabolic]
- | |
- [Lifestyle Intervention] [Lifestyle Intervention]
- + +
- [Metformin Monotherapy] [Dual Therapy: Metformin +
- 500 mg daily, titrate Sulfonylurea / SGLT2i / Basal Insulin]
- to 1000 mg BID (max 2000 mg) |
- | |
- v v
- [Review at 3 Months] [Review at 3 Months]
- Target HbA1c < 7.0% Target HbA1c < 7.0%
- |
- +-----------+-----------+
- | |
- [At Target] [Not at Target (HbA1c >= 7.0%)]
- | |
Continue Current Add Second Agent:
- Regimen • Sulfonylurea (Gliclazide / Glimepiride)
- SGLT2i (Empagliflozin / Dapagliflozin)
- Basal Insulin (10 units or 0.1-0.2 U/kg)
- Foundational Oral Antidiabetic Classes
Biguanides (Metformin):
Dosing & Administration: Initiate at 500 mg PO once daily with the evening meal. Titrate upward by 500 mg every 1 to 2 weeks to a target therapeutic dose of 1000 mg PO twice daily (maximum effective dose 2000–2550 mg daily). Administration with meals minimizes common gastrointestinal adverse effects.
Mechanism of Action: Activates AMP-activated protein kinase (AMPK), leading to decreased hepatic gluconeogenesis, decreased intestinal absorption of glucose, and enhanced peripheral insulin sensitivity in skeletal muscle.
Clinical Placement: The universal first-line pharmacological agent for all newly diagnosed Type 2 diabetes patients without contraindications. It is weight-neutral, does not cause hypoglycemia as monotherapy, and provides proven cardiovascular risk reduction.
Renal Precautions & Contraindications:
eGFR ≥ 60 mL/min \ge 60\text{ mL/min} ≥ 60 mL/min : Full dose permitted (up to 2000 mg/day); monitor renal function annually.
eGFR 45 − 59 mL/min 45 - 59\text{ mL/min} 45 − 59 mL/min : Continue full or moderate dose; monitor renal function every 3 to 6 months.
eGFR 30 − 44 mL/min 30 - 44\text{ mL/min} 30 − 44 mL/min : Reduce maximum dose by 50% (maximum 1000 mg daily ); do not initiate new patients.
eGFR < 30 mL/min < 30\text{ mL/min} < 30 mL/min : Strictly contraindicated due to impaired drug clearance leading to Metformin-Associated Lactic Acidosis (MALA).
Peri-procedural Holding: Withhold Metformin 48 hours prior to iodinated radiocontrast procedures or major surgery, resuming 48 hours post-procedure only after reconfirming stable renal function.
Sulfonylureas (Gliclazide, Glimepiride):
Agents & Dosages: Gliclazide modified-release (MR) 30–120 mg PO once daily with breakfast; Glimepiride 1–4 mg PO once daily.
Mechanism: Binds to the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, blocking ATP-sensitive K + K^+ K + channels, depolarizing the cell membrane, opening voltage-gated C a 2 + Ca^{2+} C a 2 + channels, and stimulating glucose-independent insulin exocytosis.
Clinical Placement: Cost-effective second-line add-on therapy when Metformin monotherapy fails to achieve the target HbA1c ( < 7.0 % < 7.0\% < 7.0% ) within 3 months, or first-line if Metformin is contraindicated.
Safety Warning: Glibenclamide is strongly discouraged in the elderly and patients with mild-to-moderate renal impairment due to active metabolites with prolonged half-lives causing severe, protracted hypoglycemia. Gliclazide and glimepiride have lower hypoglycemia risk.
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Empagliflozin, Dapagliflozin):
Agents & Dosages: Empagliflozin 10–25 mg PO once daily; Dapagliflozin 10 mg PO once daily.
Mechanism: Selectively inhibits SGLT2 in the proximal convoluted renal tubule, blocking glucose and sodium reabsorption, thereby inducing glucosuria (excreting 60–80 g glucose/day) and osmotic natriuresis.
Clinical Placement: Compelling indication for patients with established atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction (HFrEF), or diabetic kidney disease (proteinuria / microalbuminuria).
Adverse Effects: Vulvovaginal candidiasis, mycotic balanitis, urinary tract infections, volume depletion/orthostatic hypotension, and rare euglycemic Diabetic Ketoacidosis (euDKA) (DKA with normal or minimally elevated blood glucose levels, often triggered by acute illness, surgery, or dehydration).
Initiation of Insulin Therapy in Type 2 Diabetes
Indications for Insulin Initiation: Severe symptomatic hyperglycemia (FPG > 15.0 mmol/L > 15.0\text{ mmol/L} > 15.0 mmol/L , HbA1c > 10.0 % > 10.0\% > 10.0% , ketonuria, unintended rapid weight loss), failure of dual or triple oral therapy, acute intercurrent illness (sepsis, acute myocardial infarction, major surgery), or pregnancy.
Initiation Protocol: Begin with Basal Insulin (Intermediate-acting NPH insulin or long-acting analog Glargine/Detemir) at 10 units daily at bedtime, or weight-based dosing at 0.1 to 0.2 units/kg/day .
Titration Algorithm: Instruct the patient to check fasting blood glucose daily. Increase the basal dose by 2 units every 3 days until the fasting capillary glucose reaches the target range of 4.4 to 7.0 mmol/L . If fasting hypoglycemia occurs ( < 4.0 mmol/L < 4.0\text{ mmol/L} < 4.0 mmol/L ), reduce the basal dose by 4 units or 10%.
- 3. Diabetic Ketoacidosis (DKA) vs Hyperosmolar Hyperglycemic State (HHS)
- Pathophysiologic Differences [DIABETIC KETOACIDOSIS (DKA)] [HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)]
- | |
- [ABSOLUTE Insulin Deficiency] [RELATIVE Insulin Deficiency]
- | (Sufficient to suppress lipolysis,
- [Massive Counter-Regulatory insufficient for glucose uptake)
- Hormone Surge: Glucagon, |
- Epi, Cortisol, GH] [Extreme Hyperglycemia
- | > 33.3 mmol/L (> 600 mg/dL)]
- +--------------+--------------+ |
- | | [Massive Osmotic Diuresis]
- [Accelerated Lipolysis] [Severe Hyperglycemia] |
- | > 14.0 mmol/L [Profound Dehydration
- [Free Fatty Acid Influx] | (Fluid deficit 8-10 Liters)]
- | [Osmotic Diuresis |
- [Hepatic Ketogenesis] Fluid Deficit 4-6 L] [Extreme Hyperosmolality
- (Beta-hydroxybutyrate & | > 320 mOsm/kg]
- Acetoacetate)] | |
- | v [Altered Sensorium / Stupor]
- v [Electrolyte Wasting: |
- vvvvvvvvvvvvvvvvvvvv K+, Na+, Phos, Mg] (NO Significant Ketosis / Acidosis)
- [HIGH ANION GAP METABOLIC ACIDOSIS (pH < 7.30, HCO3 < 15, AG > 12)]
- Diagnostic Differentiation Table
Clinical / Diagnostic Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
Typical Patient Demographic Type 1 DM (can occur in severe Type 2) Elderly Type 2 DM, often bedridden or nursing home
Onset of Symptoms Rapid ( < 24 hours < 24\text{ hours} < 24 hours ) Insidious over days to weeks
Plasma Glucose > 14.0 mmol/L > 14.0\text{ mmol/L} > 14.0 mmol/L (usually 15 − 30 mmol/L 15 - 30\text{ mmol/L} 15 − 30 mmol/L ) > 33.3 mmol/L > 33.3\text{ mmol/L} > 33.3 mmol/L ( > 600 mg/dL > 600\text{ mg/dL} > 600 mg/dL ; up to 50 + mmol/L 50+\text{ mmol/L} 50 + mmol/L )
Arterial / Venous pH < 7.30 < 7.30 < 7.30 (Mild: 7.25–7.30; Moderate: 7.0–7.24; Severe: < 7.0 < 7.0 < 7.0 ) > 7.30 > 7.30 > 7.30 (usually > 7.35 > 7.35 > 7.35 )
Serum Bicarbonate ( H C O 3 − HCO_3^- H C O 3 − ) < 15 mmol/L < 15\text{ mmol/L} < 15 mmol/L (Severe: < 10 mmol/L < 10\text{ mmol/L} < 10 mmol/L ) > 18 mmol/L > 18\text{ mmol/L} > 18 mmol/L
Urine / Serum Ketones Markedly positive (>= ++) (Beta-hydroxybutyrate ≥ 3.0 mmol/L \ge 3.0\text{ mmol/L} ≥ 3.0 mmol/L ) Negative or trace
Effective Serum Osmolality Variable ( < 320 mOsm/kg < 320\text{ mOsm/kg} < 320 mOsm/kg ) > 320 mOsm/kg > 320\text{ mOsm/kg} > 320 mOsm/kg
Anion Gap ( [ N a + ] − [ C l − + H C O 3 − ] [Na^+] - [Cl^- + HCO_3^-] [ N a + ] − [ C l − + H C O 3 − ] ) Elevated ( > 12 mEq/L > 12\text{ mEq/L} > 12 mEq/L ) Normal or mildly elevated ( < 12 mEq/L < 12\text{ mEq/L} < 12 mEq/L )
- Mental Status Alert to drowsy Stupor, lethargy, or coma
- Typical Fluid Deficit 4 to 6 Liters (~100 mL/kg) 8 to 10+ Liters (~150–200 mL/kg)
Formula for Effective Serum Osmolality: Effective Osmolality (mOsm/kg) = 2 × [ Na + (mmol/L) ] + [ Glucose (mmol/L) ] \text{Effective Osmolality (mOsm/kg)} = 2 \times [\text{Na}^+ \text{ (mmol/L)}] + [\text{Glucose (mmol/L)}] Effective Osmolality (mOsm/kg) = 2 × [ Na + (mmol/L) ] + [ Glucose (mmol/L) ]
4. Stepwise Emergency DKA Resuscitation Protocol
Management of DKA rests on four synchronized pillars: aggressive fluid rehydration , low-dose regular insulin , vigilant potassium replacement , and identification of the precipitating trigger (infections [pneumonia, UTI], missed insulin doses, acute myocardial infarction, cerebrovascular events, trauma, or pregnancy).
Pillar 1: Fluid Resuscitation Protocol
Severe dehydration and hypovolemia are universal. Restoring intravascular volume is the absolute priority to reduce counter-regulatory hormone levels and restore renal perfusion:
Hour 1: Administer 1000 mL of 0.9% Normal Saline (0.9% NaCl) IV over the first hour (15–20 mL/kg/hr).
Hours 2 and 3: Infuse 1000 mL of 0.9% Normal Saline over each subsequent hour (if severe shock persists, infuse faster; if heart failure present, adjust cautiously).
Hours 4 through 8: Infuse 500 mL/hr of 0.9% Normal Saline (or 0.45% Saline if corrected serum sodium is normal or elevated).
Subsequent Infusion: 250–500 mL/hr guided by hemodynamic parameters, urine output (target > 0.5 mL/kg/hr > 0.5\text{ mL/kg/hr} > 0.5 mL/kg/hr ), and tissue turgor.
THE CRITICAL GLUCOSE THRESHOLD (14.0 mmol/L): When plasma glucose drops to below 14.0 mmol/L (250 mg/dL) , immediately change IV fluids to 5% Dextrose in 0.9% Normal Saline (or 5% Dextrose in 0.45% Saline) and adjust the insulin infusion rate to 0.05 units/kg/hr. This maintains plasma glucose between 8.0 and 12.0 mmol/L while continuing insulin to clear circulating ketoacids, preventing catastrophic brain edema and hypoglycemia.
Pillar 2: Regular (Soluble) Insulin Therapy
Pre-requisite Check: Confirm serum potassium is ≥ 3.3 mmol/L \ge 3.3\text{ mmol/L} ≥ 3.3 mmol/L before giving any insulin!
Continuous Infusion Regimen (Preferred): Administer Regular (Soluble) Insulin IV infusion at a fixed rate of 0.1 units/kg/hour (e.g., 7 units/hr for a 70 kg patient). An initial IV bolus of 0.1 units/kg is optional, but if omitted, start infusion at 0.14 units/kg/hr.
Monitoring Target: Blood glucose should decrease by 3.0 to 4.0 mmol/L per hour (50–70 mg/dL/hr). If glucose does not fall by at least 3.0 mmol/L in the first hour, verify IV access, and double the hourly insulin infusion rate.
Subcutaneous Protocol (If Syringe Pumps Unavailable): Administer Regular Insulin 0.2–0.3 units/kg subcutaneous loading dose, followed by 0.1 units/kg subcutaneous every 1 hour (or 0.2 units/kg every 2 hours).
Pillar 3: Potassium Management Protocol
Insulin promotes rapid shift of potassium from the extracellular space into cells via the N a + / K + Na^+/K^+ N a + / K + -ATPase pump. Concurrent fluid expansion dilutes serum potassium, and osmotic diuresis causes ongoing urinary potassium wasting. Serum potassium can crash precipitously: +-----------------------------------------------------------------------------------+
- | DKA POTASSIUM REPLACEMENT ALGORITHM |
- +-----------------------------------------------------------------------------------+
- | Serum Potassium (mmol/L) | Action Required |
- +--------------------------+--------------------------------------------------------+
- | < 3.3 mmol/L | HOLD INSULIN! Administer 20-40 mEq KCl/hour IV in saline|
- | | until K+ rises above 3.3 mmol/L. Only then start insulin|
- +--------------------------+--------------------------------------------------------+
- | 3.5 - 5.0 mmol/L | Add 20-30 mEq KCl per liter of IV replacement fluid. |
- | | Maintain serum K+ strictly between 4.0 and 5.0 mmol/L. |
- +--------------------------+--------------------------------------------------------+
- | > 5.0 mmol/L | Do NOT add KCl to IV fluids. Check serum K+ every 2h. |
- | | Initiate potassium replacement when K+ drops < 5.0 |
- +-----------------------------------------------------------------------------------+
- Pillar 4: Criteria for Resolution of DKA and Transition to Subcutaneous Insulin
DKA is resolved only when all the following criteria are documented:
Blood glucose < 11.1 mmol/L < 11.1\text{ mmol/L} < 11.1 mmol/L ( < 200 mg/dL < 200\text{ mg/dL} < 200 mg/dL ).
Venous blood p H > 7.30 pH > 7.30 p H > 7.30 or serum bicarbonate ≥ 18 mmol/L \ge 18\text{ mmol/L} ≥ 18 mmol/L .
Anion gap normalized ( ≤ 12 mEq/L \le 12\text{ mEq/L} ≤ 12 mEq/L ).
Patient is alert, hemodynamically stable, and tolerating oral nutrition.
Mandatory Transition Rule: Administer a subcutaneous dose of basal insulin (e.g., NPH or Glargine) 1 to 2 hours prior to discontinuing the intravenous insulin infusion . Intravenous regular insulin has a half-life of only 5 to 9 minutes; stopping the infusion without subcutaneous overlap triggers rebound ketoacidosis within 30 to 60 minutes.
- 5. Thyroid Disorders & Endocrine Emergencies
- Graves' Disease & Hyperthyroidism
Graves' disease is an autoimmune disorder driven by autoantibodies against the thyrotropin receptor (TRAb / thyroid-stimulating immunoglobulin [TSI]), resulting in autonomous excess synthesis and secretion of thyroid hormones ( T 3 T_3 T 3 and T 4 T_4 T 4 ).
Clinical Presentation: Weight loss despite increased appetite, heat intolerance, warm moist skin, fine resting tremor, sinus tachycardia or atrial fibrillation, proximal muscle weakness, hyperreflexia, and oligomenorrhea/amenorrhea. Pathognomonic extrathyroidal signs include Graves' orbitopathy (exophthalmos, periorbital edema, lid lag, chemosis) and pretibial myxedema (non-pitting, violaceous infiltrative dermopathy over the shins).
Diagnostic Laboratory Profile: Suppressed serum Thyroid-Stimulating Hormone ( TSH < 0.01 mIU/L \text{TSH} < 0.01\text{ mIU/L} TSH < 0.01 mIU/L ) accompanied by elevated free thyroxine ( FT 4 \text{FT}_4 FT 4 ) and/or free triiodothyronine ( FT 3 \text{FT}_3 FT 3 ). Diffuse vascular goiter with an audible thyroid bruit on physical examination.
Pharmacological Management:
Carbimazole: Initiated at 15 to 40 mg PO daily in divided doses, titrated down as thyroid hormone levels normalize (maintenance 5–15 mg daily). Adverse Effect Alert: Agranulocytosis occurs in 0.2–0.5% of patients; advise every patient that if they develop a sudden fever, severe sore throat, or mouth ulcers, they must immediately stop carbimazole and present for an emergency Full Blood Count.
Propylthiouracil (PTU): 100–150 mg PO 8-hourly. The preferred antithyroid drug during the first trimester of pregnancy due to carbimazole/methimazole teratogenicity (aplasia cutis, choanal atresia). Beyond the first trimester, switch back to carbimazole due to PTU-induced severe fulminant hepatotoxicity.
Symptom Control: Propranolol 20–40 mg PO 8-hourly rapidly relieves tremor, palpitations, anxiety, and tachycardia by blocking peripheral beta-adrenergic receptors and weakly inhibiting peripheral T 4 T_4 T 4 to T 3 T_3 T 3 deiodination.
Thyroid Storm (Accelerated Hyperthyroidism)
Thyroid storm is a rare, life-threatening exacerbation of thyrotoxicosis precipitated by acute systemic stress (infection, emergency surgery, trauma, DKA, childbirth, or abrupt cessation of antithyroid medication). Characterized by multi-organ decompensation and mortality exceeding 20%.
Diagnostic Recognition (Burch-Wartofsky Point Scale ≥ 45 \ge 45 ≥ 45 ): Severe hyperthermia (39.0–41.0°C), marked sinus tachycardia or atrial fibrillation ( H R > 140 bpm HR > 140\text{ bpm} H R > 140 bpm ), heart failure, agitation, acute delirium, psychosis, stupor, or coma, alongside severe vomiting, diarrhea, and jaundice.
Stepwise Multimodal Resuscitation Protocol: +-----------------------------------------------------------------------------------+
- | THYROID STORM EMERGENCY MANAGEMENT SEQUENCE |
- +-----------------------------------------------------------------------------------+
- | Step 1: Beta-Blockade | Propranolol 60-80 mg PO q4h or IV Esmolol / |
- | | Labetalol. Controls hyperadrenergic overdrive. |
- +------------------------------+-----------------------------------------------------+
- | Step 2: Block New Synthesis | Propylthiouracil (PTU) 500-1000 mg PO loading dose, |
- | | then 250 mg q4h (preferred over carbimazole because |
- | | PTU additionally inhibits peripheral T4-to-T3). |
- +------------------------------+-----------------------------------------------------+
- | Step 3: Block Hormone Release| Lugol's Iodine 5-10 drops PO q8h OR Potassium Iodide|
- | (CRITICAL TIMING RULE!) | MANDATORY RULE: Administer AT LEAST 1 HOUR AFTER |
- | | the antithyroid drug! Giving iodine first supplies |
- | | substrate for massive new thyroid hormone synthesis.|
- +------------------------------+-----------------------------------------------------+
- | Step 4: Corticosteroid Therapy| Hydrocortisone 100 mg IV q8h (or Dexamethasone 2 mg)|
- | | Blocks peripheral T4-to-T3 conversion and treats |
- | | potential relative adrenal exhaustion. |
- +------------------------------+-----------------------------------------------------+
- | Step 5: Supportive Cooling | Paracetamol and active cooling blankets. AVOID |
- | | ASPIRIN (displaces T4/T3 from TBG, worsening storm)!|
- +-----------------------------------------------------------------------------------+
- Primary Hypothyroidism & Myxedema Coma
Primary Hypothyroidism: Chronic autoimmune thyroiditis (Hashimoto's disease) and severe endemic iodine deficiency are primary drivers. Diagnostic profile reveals elevated serum TSH with low free T 4 T_4 T 4 . Manifests with fatigue, weight gain, cold intolerance, constipation, coarse dry skin, non-pitting periorbital puffiness, and delayed relaxation phase of deep tendon reflexes ('hung-up' reflexes).
Replacement Therapy: Levothyroxine (L-thyroxine) at a full replacement dose of 1.6 mcg/kg/day PO taken on an empty stomach 30–60 minutes before breakfast. In elderly patients or those with known coronary artery disease, start low ( 25 to 50 mcg daily ) and titrate upward by 12.5–25 mcg every 6 to 8 weeks to avoid precipitating angina or arrhythmias. Monitor serum TSH every 6 to 8 weeks until euthyroid.
Myxedema Coma: The end-stage, life-threatening decompensation of severe longstanding hypothyroidism. Presents with severe hypothermia ( < 35.0 ∘ C < 35.0^\circ\text{C} < 35. 0 ∘ C ) , altered mental state, bradycardia, hypoventilation (hypercapnic respiratory failure), hypotension, severe generalized non-pitting myxedematous edema, and profound hyponatremia.
Emergency Treatment: Immediate airway protection. Administer Hydrocortisone 100 mg IV 8-hourly FIRST before thyroid hormone replacement to prevent precipitating fatal acute adrenal crisis (accelerated clearance of cortisol induced by thyroid hormone in patients with concurrent autoimmune adrenal insufficiency). Administer Levothyroxine 300 to 500 mcg IV loading dose , followed by 50 to 100 mcg daily. Institute gentle, passive external rewarming with blankets (avoid active heating pads, which cause rapid peripheral vasodilation and vascular collapse).